This study investigates a treatment for individuals with pancreatic cancer.
The study evaluates the safety, tolerability, and effectiveness of an investigational treatment for pancreatic cancer. It looks at how well the treatment works and how safe it is for participants.
- Who can participate: Adults aged 18 to 75 years with locally advanced, metastatic, or recurrent pancreatic cancer can participate. Participants must have measurable disease, an ECOG performance status of 0-2, an estimated life expectancy of at least 3 months, and meet specific health criteria, including sufficient blood counts and liver function.
- Study details: Participants will receive an investigational treatment and will be monitored for safety and effectiveness.